Disseminate Recurrent Folliculitis and Hidradenitis Suppurativa Are Associated Conditions: Results From a Retrospective Study of 131 Patients With Down Syndrome and a Cohort of 12,351 Pediatric Controls.
Down syndrome
folliculitis
hair follicle disease
hidradenitis suppurativa
pediatric
Journal
Dermatology practical & conceptual
ISSN: 2160-9381
Titre abrégé: Dermatol Pract Concept
Pays: Austria
ID NLM: 101585990
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
accepted:
03
05
2019
entrez:
7
8
2019
pubmed:
7
8
2019
medline:
7
8
2019
Statut:
epublish
Résumé
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent skin disease of the pilosebaceous unit characterized by protean manifestations. Several studies have found an increased incidence and earlier presentation of this disease in patients carrying trisomy 21. Patients with Down syndrome (DS) have a higher risk of developing a wide range of cutaneous manifestations, including HS and chronic folliculitis. Recently, disseminate recurrent folliculitis (DRF) has been reported as an atypical monosymptomatic feature of HS at its onset. To assess the prevalence of HS and DRF by comparing a cohort of patients carrying trisomy 21 vs pediatric controls. A retrospective 2-year monocentric clinical study was performed by collecting clinical data of 131 patients with DS, aged 4-36 years, followed at the Dermatology Unit and Down Syndrome Regional Center of Bologna University. Data were matched with those coming from 12,351 pediatric controls. In DS patients, DRF and HS showed a prevalence of, respectively, 6.8% and 24.4%, while 5.3% of patients presented both diseases. In the control group the prevalence for HS+ and DRF+ was 0.5% and 1.2%, respectively, with a 0.14% of overlap cases. The association between HS and DRF proved to be statistically significant in both groups (P < 0.05). In the DS cohort the mean age of symptoms onset was 15.67 (SD: 2.29) years for HS and 13.11 (SD: 4.93) years for DRF. Buttocks were the most frequently affected body area for DRF followed by the inguinocrural area, while in HS buttocks were less frequently involved than groins and upper thighs. Because of the later onset of HS, patients with DRF at an early age should be monitored for the possible onset of HS in the apocrine-bearing areas.
Sections du résumé
BACKGROUND
BACKGROUND
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent skin disease of the pilosebaceous unit characterized by protean manifestations. Several studies have found an increased incidence and earlier presentation of this disease in patients carrying trisomy 21. Patients with Down syndrome (DS) have a higher risk of developing a wide range of cutaneous manifestations, including HS and chronic folliculitis. Recently, disseminate recurrent folliculitis (DRF) has been reported as an atypical monosymptomatic feature of HS at its onset.
OBJECTIVE
OBJECTIVE
To assess the prevalence of HS and DRF by comparing a cohort of patients carrying trisomy 21 vs pediatric controls.
METHODS
METHODS
A retrospective 2-year monocentric clinical study was performed by collecting clinical data of 131 patients with DS, aged 4-36 years, followed at the Dermatology Unit and Down Syndrome Regional Center of Bologna University. Data were matched with those coming from 12,351 pediatric controls.
RESULTS
RESULTS
In DS patients, DRF and HS showed a prevalence of, respectively, 6.8% and 24.4%, while 5.3% of patients presented both diseases. In the control group the prevalence for HS+ and DRF+ was 0.5% and 1.2%, respectively, with a 0.14% of overlap cases. The association between HS and DRF proved to be statistically significant in both groups (P < 0.05). In the DS cohort the mean age of symptoms onset was 15.67 (SD: 2.29) years for HS and 13.11 (SD: 4.93) years for DRF. Buttocks were the most frequently affected body area for DRF followed by the inguinocrural area, while in HS buttocks were less frequently involved than groins and upper thighs.
CONCLUSIONS
CONCLUSIONS
Because of the later onset of HS, patients with DRF at an early age should be monitored for the possible onset of HS in the apocrine-bearing areas.
Identifiants
pubmed: 31384491
doi: 10.5826/dpc.0903a03
pii: dp0903a03
pmc: PMC6659610
doi:
Types de publication
Journal Article
Langues
eng
Pagination
187-194Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
Competing interests: The authors have no conflicts of interest to disclose.
Références
Acta Derm Venereol. 1999 May;79(3):245
pubmed: 10384937
J Biol Chem. 2001 Aug 10;276(32):30018-23
pubmed: 11408475
Clin Exp Dermatol. 2001 Sep;26(6):501-3
pubmed: 11678875
Dermatology. 2002;205(3):234-8
pubmed: 12399669
Arch Dermatol. 1978 Oct;114(10):1493-4
pubmed: 152608
Am J Clin Dermatol. 2004;5(5):301-10
pubmed: 15554731
Eur J Cell Biol. 2004 Dec;83(11-12):613-24
pubmed: 15679106
Prenat Diagn. 2007 Oct;27(10):926-31
pubmed: 17602442
Clin Exp Immunol. 2009 May;156(2):189-93
pubmed: 19250275
J Am Acad Dermatol. 2011 Oct;65(4):790-798
pubmed: 21641076
J Am Acad Dermatol. 2013 Mar;68(3):412-9
pubmed: 22921795
Br J Dermatol. 2013 Apr;168(4):876-8
pubmed: 23020871
J Invest Dermatol. 2013 Jun;133(6):1506-11
pubmed: 23235532
FEBS J. 2013 May;280(10):2418-30
pubmed: 23452080
Exp Dermatol. 2013 Mar;22(3):172-7
pubmed: 23489419
Dermatol Surg. 2013 Dec;39(12):1835-42
pubmed: 24118433
Br J Dermatol. 2014 Jun;170(6):1375-7
pubmed: 24506173
J Am Acad Dermatol. 2015 Mar;72(3):485-8
pubmed: 25582541
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
Clin Dermatol. 2015 May-Jun;33(3):316-9
pubmed: 25889132
Acta Derm Venereol. 2015 Nov;95(8):990-1
pubmed: 26073615
J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S36-41
pubmed: 26470613
J Invest Dermatol. 2016 Jan;136(1):74-83
pubmed: 26763426
J Am Acad Dermatol. 2016 Sep;75(3):632-634
pubmed: 27543219
J Am Acad Dermatol. 2017 Jul;77(1):118-122
pubmed: 28285782
JAMA Dermatol. 2017 Aug 1;153(8):760-764
pubmed: 28492923
Br J Dermatol. 2018 Mar;178(3):697-703
pubmed: 28662304
J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1809-1816
pubmed: 28696038
Ann Dermatol Venereol. 2017 Nov;144(11):715-718
pubmed: 28838562
Dermatology. 2018;234(1-2):66-70
pubmed: 29689550
J Appl Res Intellect Disabil. 2018 Nov;31(6):1225-1229
pubmed: 29761882
Am J Clin Dermatol. 2018 Oct;19(5):733-757
pubmed: 30043128
Arch Dermatol. 1988 Jul;124(7):1047-51
pubmed: 3291777
J Am Acad Dermatol. 1988 Jan;18(1 Pt 1):31-7
pubmed: 3346406
Br J Dermatol. 1986 Sep;115(3):259-62
pubmed: 3756090
Br J Dermatol. 1993 Dec;129(6):696-9
pubmed: 8286253
J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):191-4
pubmed: 8708018